Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany
 
 
 
This Media Center provides you with the latest news about our Oncology Franchise and related disease information.

  
 

Media Center - Oncology

Media Fact Sheets

TopicDownload
Gastroesophageal Junction CancerPDF
Ovarian CancerPDF
Merkel Cell CarcinomaPDF
Gastric cancerPDF
Bladder CancerPDF
Lung cancerPDF
Renal cell carcinomaPDF
MesotheliomaPDF
Following media fact sheets are available on request.
  • Avelumab
.
top

Animations

Gastric Cancer: Signs and Symptoms
Gastric Cancer: Signs and Symptoms
Lung Cancer: Facts and Figures
Lung Cancer: Facts and Figures
Merkel Cell Carcinoma: Facts and Figures
Merkel Cell Carcinoma: Facts and Figures
Merkel Cell Carcinoma: Signs and Symptoms
Merkel Cell Carcinoma: Signs and Symptoms
Ovarian Cancer: Facts and Symptoms
Ovarian Cancer: Facts and Symptoms
Renal Cell Carcinoma: Facts and Symptoms
Renal Cell Carcinoma: Facts and Symptoms
Malignant Mesothelioma: Facts and Figures
Malignant Mesothelioma: Facts and Figures
.
top

Images

AVELUMAB MOLECULE

Avelumab molecule
.
top

News Releases Oncology

Follow the link to read more

2017/03/23   
FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma

2017/01/23   
Merck KGaA, Darmstadt, Germany, Announces Research Collaboration with Domain Therapeutics in Immuno-Oncology

2017/01/11   
Merck KGaA, Darmstadt, Germany, Licenses Four Oncology Research and Development Programs from Vertex and Becomes a Leader in DNA Damage and Repair

2017/01/09  
EMD Serono and MD Anderson Cancer Center Enter Three-Year Strategic Collaboration

2016/11/01  
Merck KGaA, Darmstadt, Germany, Partners with American Cancer Society to Address Cancer in Women

2016/09/28  
Merck KGaA, Darmstadt, Germany to Present New Research Focused on Hard-to-Treat Cancers at ESMO 2016

2016/07/06
Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

2016/06/06
ASCO 2016: Pivotal Avelumab Study Shows Positive Results in Metastatic Merkel Cell Carcinoma

2016/05/18
Merck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting

2016/04/14
Merck KGaA, Darmstadt, Germany, Appoints Maya Martinez-Davis as Global Head of Oncology

2016/03/03
Merck KGaA, Darmstadt, Germany, Pfizer and Verastem Announce Combination Trial of Avelumab and VS-6063 in Ovarian Cancer

2016/03/03
Merck KGaA, Darmstadt, Germany and Biocartis to Collaborate on New Liquid Biopsy Technology for RAS Biomarker Testing

2016/01/04
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
There are two different, unaffiliated companies that use the name MERCK. Merck KGaA, Darmstadt, Germany, which operates this website, uses the firm name “Merck KGaA, Darmstadt, Germany,” in the United States and Canada, and also uses “EMD Serono” in biopharma, “MilliporeSigma” in life science and “EMD Performance Materials” in materials business. The other company, Merck & Co., Inc. holds the rights in the trademark MERCK in the United States and Canada. Merck & Co. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the MERCK trademark in all other countries of the world.   To reflect such fact and to avoid any confusion, certain logos, terms and business descriptions of the publications on this website have been substituted or modified, such as by referring to “Merck KGaA, Darmstadt, Germany” instead of “Merck” standing alone.  Publications on this webpage, therefore, slightly deviate from the otherwise identical versions accessible outside the United States and Canada.
 

CONTACT

Are you interested in interviewing a internal spokesperson or an oncology expert? Please get in contact with us.
Gangolf Schrimpf
GANGOLF SCHRIMPF
Tel: +49 6151 72-9591
Fax: +49 6151 72-919591